anti il 12  (Bioss)

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: ELF5 regulate casein synthesis in GMECs. (A, B) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, phosphorylated JAK2 and STAT5 after transfection with pcDNA3.1-ELF5 or pcDNA3.1-NC for 48 h. (C, D) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, p-JAK2, and p-STAT5 after transfection with siRNA-ELF5 or siRNA-NC (100 nM) for 48 h. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-JAK2 and p-STAT5 was normalized to total JAK2 and STAT5, respectively. Values are presented as mean±SEM. * p<0.05, ** p<0.01. siRNA, small interfering ribonucleic acid; NC, negative control; GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Expressing, Transfection, Quantitative Proteomics, Negative Control

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: The protein abundance of caseins after JAK2 and STAT5 inhibition in GMECs. (A) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, and phosphorylated JAK2 and STAT5 after JAK2 inhibitor Tyrphosting AG490 (30 μM) treatment for 48 h. (B) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, and p-STAT5 after STAT5 inhibitor STAT5-IN-1 (50 μM) treatment for 48 h. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-JAK2 and p-STAT5 was normalized to total JAK2 and STAT5, respectively. Values are presented as mean±SEM. ** p<0.01. GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Quantitative Proteomics, Inhibition, Expressing

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: ELF5 mediates casein synthesis by STAT5 activity in GMECs. (A) Cells were treated with STAT5-IN-1 (50 μM) or DMSO, followed by pcDNA3.1-ELF5 or pcDNA3.1-NC transfection for 48 h. (B) Cells were treated with STAT5-IN-1 (50 μM) or DMSO, followed by siRNA-ELF5 or siRNA-NC (100 nM) transfection for 48 h. The protein abundances of αS1-casein, αS2-casein, β-casein, κ-casein, and p-STAT5 were detected. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-STAT5 was normalized to total STAT5. Values are presented as mean±SEM. a–d Different lowercase letters represent significant differences (* p<0.05). siRNA, small interfering ribonucleic acid; NC, negative control; GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Activity Assay, Transfection, Quantitative Proteomics, Negative Control

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: ELF5 mediates casein synthesis by JAK2 and STAT5 activity in GMECs. (A) Cells were treated with Tyrphosting AG490 (30 μM) or DMSO, followed by pcDNA3.1-ELF5 or pcDNA3.1-NC transfection for 48 h. (B) Cells were treated with Tyrphosting AG490 (30 μM) or DMSO, followed by siRNA-ELF5 or siRNA-NC (100 nM) transfection for 48 h. The protein abundances of αS1-casein, αS2-casein, β-casein, κ-casein, p-JAK2, and p-STAT5 were detected. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-JAK2 and p-STAT5 was normalized to total JAK2 and STAT5, respectively. Values are presented as mean±SEM. a–d Different lowercase letters represent significant differences (* p<0.05). NC, negative control; siRNA, small interfering ribonucleic acid; GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Activity Assay, Transfection, Quantitative Proteomics, Negative Control

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: ELF5 regulate casein synthesis in GMECs. (A, B) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, phosphorylated JAK2 and STAT5 after transfection with pcDNA3.1-ELF5 or pcDNA3.1-NC for 48 h. (C, D) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, p-JAK2, and p-STAT5 after transfection with siRNA-ELF5 or siRNA-NC (100 nM) for 48 h. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-JAK2 and p-STAT5 was normalized to total JAK2 and STAT5, respectively. Values are presented as mean±SEM. * p<0.05, ** p<0.01. siRNA, small interfering ribonucleic acid; NC, negative control; GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Expressing, Transfection, Quantitative Proteomics, Negative Control

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: The protein abundance of caseins after JAK2 and STAT5 inhibition in GMECs. (A) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, and phosphorylated JAK2 and STAT5 after JAK2 inhibitor Tyrphosting AG490 (30 μM) treatment for 48 h. (B) The expression of αS1-casein, αS2-casein, β-casein, κ-casein, and p-STAT5 after STAT5 inhibitor STAT5-IN-1 (50 μM) treatment for 48 h. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-JAK2 and p-STAT5 was normalized to total JAK2 and STAT5, respectively. Values are presented as mean±SEM. ** p<0.01. GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Quantitative Proteomics, Inhibition, Expressing

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: ELF5 mediates casein synthesis by STAT5 activity in GMECs. (A) Cells were treated with STAT5-IN-1 (50 μM) or DMSO, followed by pcDNA3.1-ELF5 or pcDNA3.1-NC transfection for 48 h. (B) Cells were treated with STAT5-IN-1 (50 μM) or DMSO, followed by siRNA-ELF5 or siRNA-NC (100 nM) transfection for 48 h. The protein abundances of αS1-casein, αS2-casein, β-casein, κ-casein, and p-STAT5 were detected. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-STAT5 was normalized to total STAT5. Values are presented as mean±SEM. a–d Different lowercase letters represent significant differences (* p<0.05). siRNA, small interfering ribonucleic acid; NC, negative control; GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Activity Assay, Transfection, Quantitative Proteomics, Negative Control

Journal: Animal Bioscience

Article Title: ELF5 modulates casein synthesis in goat mammary epithelial cells via JAK2/STAT5 signaling pathway

doi: 10.5713/ab.25.0181

Figure Lengend Snippet: ELF5 mediates casein synthesis by JAK2 and STAT5 activity in GMECs. (A) Cells were treated with Tyrphosting AG490 (30 μM) or DMSO, followed by pcDNA3.1-ELF5 or pcDNA3.1-NC transfection for 48 h. (B) Cells were treated with Tyrphosting AG490 (30 μM) or DMSO, followed by siRNA-ELF5 or siRNA-NC (100 nM) transfection for 48 h. The protein abundances of αS1-casein, αS2-casein, β-casein, κ-casein, p-JAK2, and p-STAT5 were detected. The relative protein abundance of αS1-casein, αS2-casein, β-casein, and κ-casein was normalized to β-tubulin. The relative protein abundance of p-JAK2 and p-STAT5 was normalized to total JAK2 and STAT5, respectively. Values are presented as mean±SEM. a–d Different lowercase letters represent significant differences (* p<0.05). NC, negative control; siRNA, small interfering ribonucleic acid; GMECs, goat mammary epithelial cells; SEM, standard error of the mean.

Article Snippet: Primary antibodies contains ELF5 (sc-166653, SantaCruz; 1:1,000), αS2-casein (bs-10034R, Bioss; 1:2,000), κ-casein (bs-10031R; Bioss; 1:1,000), αS1-casein (bs-10033R; Bioss; 1:1,000), β-casein (sc-166530; SantaCruz; 1:1,000), p-JAK2 (ab32101; Abcam; 1:1,000), p-STAT5 (9351S; 1:1,000), JAK2 (3230; CST; 1:1,000), STAT5 (610191; BD; 1:1,000), proliferating cell nuclear antigen (PCNA, 10205-2-APl Proteintech, 1:5,000), cyclin dependent kinase 2 (CDK2, 10122-1-AP; Proteintech, 1:10,000), B-cell lymphoma-2-associated X (BAX, 50599-2-lg; Proteintech, 1:10,000), Caspase3 (19677-1-AP; Proteintech, 1:2,000), β-Tubulin (CW0098M; CWBIO, 1:5,000).

Techniques: Activity Assay, Transfection, Quantitative Proteomics, Negative Control

Journal: PeerJ

Article Title: UBE2S and HIF1α expression patterns and stratified analysis reveal prognostic value in esophageal squamous cell carcinoma

doi: 10.7717/peerj.20694

Figure Lengend Snippet: (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) HIF1 α staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.

Article Snippet: The primary antibodies used were: UBE2S (rabbit polyclonal, 14115-1-AP, 1:360; Proteintech), HIF1 α (rabbit monoclonal, bs-0737R, 1:400; BIOSS), and p110 α (rabbit polyclonal, C73F8, 1:250; ZSGB-Bio).

Techniques: Staining

Journal: PeerJ

Article Title: UBE2S and HIF1α expression patterns and stratified analysis reveal prognostic value in esophageal squamous cell carcinoma

doi: 10.7717/peerj.20694

Figure Lengend Snippet: (A, B) Pan-cancer mRNA expression analysis of UBE2S (A) and HIF1 α (B) across TCGA malignancies, indicating significant overexpression in ESCA. (C, D) Validation of UBE2S (C) and HIF1 α (D) mRNA overexpression in the TCGA-ESCA tumor cohort compared to a pooled normal tissue reference (integrating GTEx data; p < 0.001, Wilcoxon rank-sum test). (E, F) Independent validation in the GEO dataset ( GSE161533 ) confirms significant overexpression of UBE2S (E) and HIF1 α (F) in ESCC tissues compared to paired adjacent non-tumorous tissues ( p < 0.001). (G) Correlation analysis within the TCGA-ESCA cohort reveals a significant positive correlation between UBE2S and HIF1 α mRNA expression levels (Pearson’s correlation; R = 0.42, p = 0.0013).

Article Snippet: The primary antibodies used were: UBE2S (rabbit polyclonal, 14115-1-AP, 1:360; Proteintech), HIF1 α (rabbit monoclonal, bs-0737R, 1:400; BIOSS), and p110 α (rabbit polyclonal, C73F8, 1:250; ZSGB-Bio).

Techniques: Expressing, Over Expression, Biomarker Discovery

Journal: PeerJ

Article Title: UBE2S and HIF1α expression patterns and stratified analysis reveal prognostic value in esophageal squamous cell carcinoma

doi: 10.7717/peerj.20694

Figure Lengend Snippet: (A, B) Kaplan–Meier survival curves showing that high expression of UBE2S is significantly associated with poorer overall survival (OS; p = 0.006) and progression-free survival (PFS; p = 0.034). (C, D) Similarly, high expression of HIF1 α is associated with reduced OS ( p < 0.001) and PFS ( p = 0.002). (E, F) Patients were stratified into four groups based on UBE2S and HIF1 α co-expression status: Group 1 (dual-negative), Group 2 (UBE2S-negative/HIF1 α -positive), Group 3 (UBE2S-positive/HIF1 α -negative), and Group 4 (dual-positive). Kaplan–Meier analysis revealed significant stratification of both OS ( p < 0.001) and PFS ( p = 0.005) among these groups, with patients exhibiting dual-positive expression (Group 4) demonstrating the poorest outcomes.

Article Snippet: The primary antibodies used were: UBE2S (rabbit polyclonal, 14115-1-AP, 1:360; Proteintech), HIF1 α (rabbit monoclonal, bs-0737R, 1:400; BIOSS), and p110 α (rabbit polyclonal, C73F8, 1:250; ZSGB-Bio).

Techniques: Expressing